Search research articles
Contact Us
Filters
Showing results (61-70 of 104) with videos related to
Page
of 11
Sort By:
Future Oncology (London, England)
|
April 18, 2023
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i>-mutant breast cancer during first-line treatment
Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment
|
January 23, 2025
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer
Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Breast Cancer Research : BCR
|
August 27, 2013
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
Judith-Anne W Chapman, Torsten O Nielsen, Matthew J Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163
Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
British Journal of Cancer
|
June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
Howard A Burris, Arlene Chan, Aditya Bardia, et al.
Frontiers in Oncology
|
February 17, 2023
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
Serena Di Cosimo, Chiara M Ciniselli, Sara Pizzamiglio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Oncogene
|
July 20, 2005
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis
Leah M Prentice, Ashleen Shadeo, Valia S Lestou, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
Jeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
The Lancet. Oncology
|
April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 104) with videos related to
Sort By:
Page
of 11
Future Oncology (London, England)
|
April 18, 2023
Design of SERENA-6, a phase III switching trial of camizestrant in <i>ESR1</i>-mutant breast cancer during first-line treatment
Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, et al.
Breast Cancer Research and Treatment
|
January 23, 2025
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer
Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, et al.
Breast Cancer Research : BCR
|
August 27, 2013
Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort
Judith-Anne W Chapman, Torsten O Nielsen, Matthew J Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163
Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
British Journal of Cancer
|
June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
Howard A Burris, Arlene Chan, Aditya Bardia, et al.
Frontiers in Oncology
|
February 17, 2023
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
Serena Di Cosimo, Chiara M Ciniselli, Sara Pizzamiglio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Oncogene
|
July 20, 2005
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis
Leah M Prentice, Ashleen Shadeo, Valia S Lestou, et al.
Current Oncology (Toronto, Ont.)
|
November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
Jeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.
The Lancet. Oncology
|
April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Page
of 11